Pathos AI
-
Business & Markets Pathos AI Secures $237M in Series E Financing to Scale Agentic AI Drug Development Platform and Advance Oncology Pipeline
Insider Brief PRESS RELEASE — Pathos AI, Inc., a clinical-stage AI and technology company advancing its own therapeutic pipeline of drugs, announced the closing of a $237 million Series E financing round at a post-money valuation… -
Business & Markets · Startups Pathos AI Closes $62M Oversubscribed Series C Round of Financing to Accelerate its Platform Approach to Drug Development
The AI economy, every weekday morning
The daily briefing plus the weekly Scale-ups to watch edition. Free, no spam, unsubscribe any time.